Study to Collect Blood Samples for Developing a Device to Grow and Test Immune and Tumor Cells from Cancer Patients and Healthy Volunteers

What this Trial Is About

Researchers are investigating the feasibility of collecting and expanding T lymphocytes from both cancer patients and healthy volunteers. The study aims to select specific immune cells marked by PD-1 and CTLA4 from the blood and assess their ability to kill tumor cells outside the body. This observational study includes adults with any stage of solid tumors, healthy volunteers, and individuals with COVID-19, with special provisions for pediatric participants aged 5 to 17 years. Participants are divided into three groups cancer patients receiving routine care, healthy volunteers who help optimize study procedures, and COVID-19 patients whose participation may be limited based on their condition. Adults and pediatric participants undergo blood and other minimally invasive biospecimen collections, including leukapheresis for eligible adults, to obtain immune and tumor cells. The study supports quality control, assay development, and device validation across cohorts. During the study, participants provide biospecimens such as blood, saliva, urine, and swabs. Researchers will analyze these samples to evaluate immune cell function and develop an ex-vivo device platform for culture, immune testing, and biobanking. The study collects clinical information and laboratory test results, including infection status and organ function markers. Participation requires informed consent and may include repeated sampling over time to support ongoing research efforts.

A Biospecimen Collection Study of Leukapheresis-Derived Circulating Tumor Cells, Immune Cells, and Progenitor Cells.